Regulatory Approvals

Recon: FDA approves GSK hepatitis B drug; EQT to buy molecular testing firm Qiagen for $10.8B

By

Regulatory Approvals — Recon: FDA approves GSK hepatitis B drug; EQT to buy molecular testing firm Qiagen for $10.8B  RAPS

Read the original at Regulatory Approvals ↗

Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. October 22, 2026.

By

Related Post

Regulatory Approvals

FDA Approves Pembrolizumab in Metastatic TMB-H Solid Tumors

Regulatory Approvals

FDA Approves Berotralstat Oral Pellets for Adults, Adolescents With HAE

Regulatory Approvals

FDA Approves First Generic Hormone Therapy Patch

Financial News For All

Mergers & Acquisitions

SpaceX and Tesla Are Already Joined at the Hip. What a Formal Merger Would Mean.

Mergers & Acquisitions

As Exits Continue, Weil Works on Merger Deal, Tells Partners to Carry On

Labor

California State University faculty union asks members for strike authorization

Labor

Novolex Evergreen strike in Cedar Rapids ends